Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus abiraterone and prednisone versus placebo plus abiraterone and prednisone in high-risk metastatic hormone-sensitive prostate cancer
MOH_2022-05-17_010809Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abemaciclib, abiraterone and prednisone in prostate cancer (PCa) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Radiographic disease progression. Started Apr 2022; status: active, not recruiting.
02
Drugs
abemaciclibabirateroneprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2022-05-17_010809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-17_010809.